Asclera Gets Approval For Varicose Veins

Last year, we reported that a more comfortable sclerotherapy solution was in FDA trials for the treatment of varicose veins. This injectable drug, polidocanol, was recently approved by the FDA and is now available as Asclera.

"Asclera is indicated for the treatment of small types of varicose veins when the aim of treatment is to improve appearance," explained Norman Stockbridge, MD, PhD, director of the Division of Cardiovascular and Renal Products at the FDA's Center for Drug Evaluation and Research.

It works by irritating or damaging the lining of the blood vessel, which then causes those vessels to close and eventually be replaced by other tissue. This leads to the varicose veins, which appear swollen and twisted, looking less obvious.

The risks are comparable to existing sclerotherapy solutions, but Asclera is reportedly less painful that of sodium tetradecyl sulfate, the most commonly used sclerosant.